SVB Wealth LLC Makes New $302,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

SVB Wealth LLC purchased a new position in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 2,430 shares of the medical device company’s stock, valued at approximately $302,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bartlett & CO. Wealth Management LLC purchased a new position in DexCom in the fourth quarter worth $27,000. Valley National Advisers Inc. grew its holdings in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. Harbour Investments Inc. grew its holdings in shares of DexCom by 55.6% during the third quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock valued at $31,000 after buying an additional 120 shares during the last quarter. Atlas Capital Advisors LLC purchased a new stake in shares of DexCom during the second quarter valued at $33,000. Finally, MV Capital Management Inc. grew its holdings in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. In the last quarter, insiders sold 189,375 shares of company stock valued at $25,530,859. Corporate insiders own 0.41% of the company’s stock.

DexCom Stock Down 2.7 %

DXCM opened at $130.71 on Monday. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. The company has a 50-day moving average price of $129.55 and a 200 day moving average price of $117.04. The company has a market cap of $50.39 billion, a PE ratio of 99.78, a price-to-earnings-growth ratio of 2.25 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the prior year, the firm earned $0.34 EPS. The company’s revenue for the quarter was up 26.9% on a year-over-year basis. Sell-side analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on DXCM shares. Raymond James boosted their price objective on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. Royal Bank of Canada assumed coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. UBS Group upped their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Finally, Citigroup upped their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.